Karolinska Institute under fire for controversial cancer report

Abstract

The gene therapy trial during which a 36-year-old Illinois woman died in July was inappropriately designed, experts said at the 17 September meeting of the government panel investigating her death. Researchers affiliated with Seattle-based Targeted Genetics injected a gene therapy treatment into Jolee Mohr’s right knee first in February and again on 2 July. On 24 July, Mohr died. The immediate cause of her death was massive bleeding behind the kidneys from unknown causes, which led to the collapse of multiple organs. Her body was also overwhelmed by a fungal infection known as histoplasmosis, which can kill people with deficient immune systems. Mohr had also been taking Humira (adalimumab), an injectable protein that eases the symptoms of rheumatoid arthritis throughout the body by blocking a protein called TNF-alpha. The gene therapy product

DOI: 10.1038/nm1007-1124b

Cite this paper

@article{Willyard2007KarolinskaIU, title={Karolinska Institute under fire for controversial cancer report}, author={Cassandra Willyard}, journal={Nature Medicine}, year={2007}, volume={13}, pages={1124-1124} }